AFEMS
ActiveSummary
For the legal form of AFEMS, Checked does not compute a bankruptcy probability. The 2025 annual accounts show equity of €612,171 and a net result of €23,532. Equity is growing by ~7.5% per year across the filed fiscal years. Its solvency ranks better than 60% of 526 sector peers (fiscal year 2025). The company has been active since 1984 and the Belgian State Gazette contains no insolvency or warning signals.
Checked score
Score 2025
Axes · tick = 2024
Profitability44▼-13
Solvency96=
Growth52▼-26
Track record100
Credit verdict
Credit up to €45,000 at 30 days acceptable
Liquidity ample (current ratio 29.01 against 36.16 in 2024; short-term debt: 3.4% and cash: 78.1% of total assets), and 29.1% of the assets are financed with debt.
Credit check for your own amount and term
Show the recommended maximum : and see how the verdict changes with amount, term and advance.
Signals
1 signal. The signal on the left, the evidence on the right.
○neutral
neutral · Latest accounts filed on time
The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 01-07-2026, 30 days ahead of the deadline.
NBB · 3 filingsDeviation from the deadline
2025
30 d early
2024
13 d late
2023
8 d early
← before the deadline
after the deadline →
tick = median of all Belgian filingsring = median in the sector
This company filed its last 3 accounts on average 8 days before the deadline; the sector median for financial year 2024 is 13 days before the deadline, and 32% of the sector filed late.
Checked, nothing found (2)
neutral · The next deadline is still running
The next financial year closes on 31-12-2026 and is due by 31-07-2027. Nothing is late today. Usually files around 24 July (3 of the last 3 filed years within 30 days of that day).
Companies Code · seven monthsPosition in the running window
29-09-2026 today31-12-2026 close31-07-2027 deadline
History
Go further with this company
How much credit can you give this customer, and on what term?Credit check What should you check before you do business with this company?Supplier due diligence Can you accept this company as a client under the anti-money-laundering law?AML client file Which of your other customers can you e-invoice via Peppol?Peppol check How does this company compare with its sector?Sector benchmark What changed in the latest annual accounts?What changed
Is this your company? See how customers and banks see it.
Investigating this company? Keep it with today's facts in a case file.
Financials · fiscal year 2025, micro schema
Equity
€612,171▲ 4.0%
2024 · €588,639
Total assets
€863,868▲ 3.6%
2024 · €833,607
Net result
€23,532▼ 63.8%
2024 · €64,959
Working capital
€834,088▲ 2.9%
2024 · €810,556
Trend over the years
Click a name to add, emphasise or remove a line.Band: the middle half (P25 to P75) of NACE 72, Scientific research and development, each year against the same schema; no band under 30 filings. Dashed line: the median.
Every figure with its change against the fiscal year before
favourable
unfavourable
Line202320242025
Operating result€48,898-€52,603▲ 7.6%€15,873▼ 69.8%
Net result€48,797within the sector's middle half-€64,959within the sector's middle half▲ 33.1%€23,532within the sector's middle half▼ 63.8%
Equity€523,680above the sector's middle half-€588,639above the sector's middle half▲ 12.4%€612,171above the sector's middle half▲ 4.0%
Total assets€781,051above the sector's middle half-€833,607above the sector's middle half▲ 6.7%€863,868above the sector's middle half▲ 3.6%
Debt€257,371-€244,968▼ 4.8%€251,697▲ 2.7%
Working capital€745,597above the sector's middle half-€810,556above the sector's middle half▲ 8.7%€834,088above the sector's middle half▲ 2.9%
Solvency67.0%within the sector's middle half-70.6%within the sector's middle half▲ 3.6pp70.9%within the sector's middle half▲ 0.3pp
Current ratio22.03above the sector's middle half-36.16above the sector's middle half▲ 14.1329.01above the sector's middle half▼ 7.16
Return on assets (ROA)6.2%within the sector's middle half-7.8%within the sector's middle half▲ 1.5pp2.7%within the sector's middle half▼ 5.1pp
above
within
below
the middle half (P25 to P75) of NACE 72, Scientific research and development, each year against the same schema; no band under 30 filings.
Turnover and EBIT margin not published: the micro schema does not require them.
Result per fiscal year
Operating resultNet result
The operating result falls in 2025; 2025 is 70% below 2024 and is the lowest result in the available series.
Balance-sheet composition
2025 in colour, 2024 as the grey bar beneath
Equity and liabilities €863,868
Equity
€612,171 ▲ 4.0%
Debt
€251,697 ▲ 2.7%
Debt's share of the balance-sheet total falls from 29.4% to 29.1%. Equity and debt are higher.
Key figures and ratios
Debt to equity
0.41▼
2024 · 0.42
ROE
3.8%▼
2024 · 11.0%
Debt ≤ 1 year
€29,780▲
2024 · €23,050
Green means a favourable move, even when the figure itself falls: as with debt or debt to equity.
Annual accounts
| Line | 2023 | 2024 | 2025 | Change |
|---|---|---|---|---|
| Write-downs on stocks, contracts in progress and trade receivables: additions (reversals)631/4 | €24,824 | - | - | - |
| Gross operating margin9900 | €73,723 | €52,603 | €15,873 | ▼ 69.8% |
| Operating profit (loss)9901 | €48,898 | €52,603 | €15,873 | ▼ 69.8% |
| Financial income75/76B | €600 | €14,130 | €9,194 | ▼ 34.9% |
| Recurring financial income75 | €600 | €14,130 | €9,194 | ▼ 34.9% |
| Financial charges65/66B | €701 | €1,774 | €1,535 | ▼ 13.5% |
| Recurring financial charges65 | €701 | €1,774 | €1,535 | ▼ 13.5% |
| Profit (loss) for the period before taxes9903 | €48,797 | €64,959 | €23,532 | ▼ 63.8% |
| Profit (loss) for the period9904 | €48,797 | €64,959 | €23,532 | ▼ 63.8% |
| Profit (loss) for the period to be appropriated9905 | €48,797 | €64,959 | €23,532 | ▼ 63.8% |
| Line | 2023 | 2024 | 2025 | Change |
|---|---|---|---|---|
| Assets | ||||
| Total assets20/58 | €781,051 | €833,607 | €863,868 | ▲ 3.6% |
| Current assets29/58 | €781,051 | €833,607 | €863,868 | ▲ 3.6% |
| Amounts receivable within one year40/41 | €94,274 | €95,361 | €184,693 | ▲ 93.7% |
| Trade receivables40 | €86,437 | €64,688 | €160,555 | ▲ 148% |
| Other amounts receivable41 | €7,837 | €30,673 | €24,139 | ▼ 21.3% |
| Current investments50/53 | - | €550,000 | - | - |
| Cash at bank and in hand54/58 | €686,777 | €186,344 | €674,995 | ▲ 262% |
| Deferred charges and accrued income490/1 | - | €1,902 | €4,179 | ▲ 120% |
| Equity and liabilities | ||||
| Total equity and liabilities10/49 | €781,051 | €833,607 | €863,868 | ▲ 3.6% |
| Equity10/15 | €523,680 | €588,639 | €612,171 | ▲ 4.0% |
| Contributions10/11 | €66,934 | €66,934 | €66,934 | = |
| Capital10 | €66,934 | €66,934 | €66,934 | = |
| Profit (loss) carried forward14 | €456,746 | €521,704 | €545,236 | ▲ 4.5% |
| Amounts payable17/49 | €257,371 | €244,968 | €251,697 | ▲ 2.7% |
| Amounts payable within one year42/48 | €35,453 | €23,050 | €29,780 | ▲ 29.2% |
| Trade debts44 | €35,453 | €23,050 | €29,780 | ▲ 29.2% |
| Suppliers440/4 | €35,453 | €23,050 | €29,780 | ▲ 29.2% |
| Accrued charges and deferred income492/3 | €221,917 | €221,917 | €221,917 | = |
| Line | 2023 | 2024 | 2025 | Change |
|---|---|---|---|---|
| Profit (loss) for the period9904 | €48,797 | €64,959 | €23,532 | ▼ 63.8% |
| Operating cash flow (approximation) | €48,797 | €64,959 | €23,532 | ▼ 63.8% |
| Change in cash | - | -€500,433 | €488,652 | ▲ 198% |
Simplified and derived: a Belgian filing has no cash-flow statement, so these rows come from the income statement and the balance-sheet moves.
Timeline · acts, filings and financial milestones
Next filing, fiscal year 2026, expected by
2026
01-07
NBB filing
Annual accounts filed
fiscal year 2025 · micro schema
2025
31-12
Financial
Weakest financial yearnet €23,532 ▼63.8%
Net result drops to €23,532, the lowest in the series.
13-08
NBB filing
Annual accounts filed
fiscal year 2024 · micro schema · 13 days late
2024
31-12
Financial
Highest result since 2023net €64,959 ▲33.1%
Operating result €52,603, net result €64,959, both a record.
23-07
NBB filing
Annual accounts filed
fiscal year 2023 · micro schema
Financial milestoneNBB filingFinancial milestones sit on the fiscal year-end date, not the filing date.
Directors · office · real estate
Directors
We have established no sitting directors for this company. We derive directors from published Gazette acts; while there are none, or none read, nothing appears here. That does not mean the company has none: the CBE keeps its own list of function holders, which we do not read.
Location & real-estate footprint
Registered office, Oudergem
Ground area
9,604 m²
Building footprint
1,500 m²
Volume, LiDAR
601 m³
Parcel 21332B0498/00A000, Brussels · tallest building 8.5 m. Linked by address, not a title deed.
1 parcel
Brussels
1
(100%)
| Parcel (capakey) | Region | Area | Buildings | Height / fl. |
|---|---|---|---|---|
| 21332B0498/00A000 | Brussels | 9,604 m² | 1 · 1,500 m² | 8.5 m |
Linked by address, not proof of ownership
Good to know
1 of 1 parcel with an exact address match; the rest are indicative.
Linked through address data, this is not proof of ownership.
Similar companies · same sector, comparable size
Vlaams Centrum voor Bewaring van Tuinbouwproducten
BE 0460.704.171
Leuven · Eq €613,327
ENDO TOOLS THERAPEUTICS
BE 0807.570.233
Charleroi · Eq €609,167
Eastman Chemical Technology
BE 0671.793.393
Gent · Eq €616,866
PSI CRO BELGIUM
BE 0599.913.920
Leuven · Eq €617,185
EPPENDORF APPLICATION TECHNOLOGIES
BE 0466.454.390
Namur · Eq €600,133
Of 1,177 companies in sector 72109 we hold annual accounts for 717. 483 are within a factor 10 of this equity. The 5 above are the closest to it. See the whole sector
Identification & contact
Identification
Legal formTijdelijke vereniging
Founded01-03-1984
Fiscal year end31-12
Activities, NACEBEL 2025
72109Other research and development on natural sciences
E-invoicing
Reachable via Peppol
Peppol ID
0208:0544172968
Registered
31-12-2025
If you follow this company, Checked tells you the day it leaves the Peppol register.
Register as of 29 September 2026 · Peppol Directory
Scores and ratios are computed by Checked and are not a credit decision.